中国麻风皮肤病杂志 ›› 2019, Vol. 35 ›› Issue (3): 184-188.doi: 10.12144/zgmfskin201903184

• 综述 • 上一篇    下一篇

特应性皮炎的生物学分型及靶向治疗进展

陈嘉雯  姚志荣   

  1. 上海交通大学医学院附属新华医院皮肤科，上海，200092
  • 出版日期:2019-03-15 发布日期:2019-04-09
  • 通讯作者: 姚志荣，E-mail:：yaozhirong@xinhuamed.com.cn

Update of atopic dermatitis endotypes and targeted therapies

CHEN Jiawen, YAO Zhirong   

  1. Department of Dermatology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
  • Online:2019-03-15 Published:2019-04-09
  • Contact: YAO Zhirong, E-mail: yaozhirong@xinhuamed.com.cn

PDF (PC)

317

摘要： 特应性皮炎是一种常见的慢性炎症性皮肤疾病，被认为由Th2型免疫反应主导。有研究发现特应性皮炎患者在年龄、种族、内外源性等方面存在明显异质性，从而分为不同的生物学亚型。在不同生物学亚型的特应性皮炎中Th22、Th17和Th1型免疫反应的活化程度不同，治疗特应性皮炎的靶向药物可按靶点不同分为靶向Th2型细胞因子、靶向非Th2型细胞因子、靶向小分子型。本文综述了特应性皮炎的生物学分型及靶向药物的研究现状。

关键词: 特应性皮炎, 生物学分型, 靶向治疗

Abstract: Atopic dermatitis (AD), a common chronic inflammatory skin disease, is recognized to be driven by overactive type 2 immune response. Recent studies revealed that the heterogeneity of AD including age of onset, race and intrinsic/extrinsic and different encotypes were indentified. Activation of Th22, Th17/IL-23 and Th1 cytokine pathway  varies in different encotypes and the targeted therapies are different accordingly. The update of AD encotypes and the targeted therapies is reviewed.

Key words: atopic dermatitis, encotype, targeted therapy